John Dobak, M.D.
President and CEO
John Dobak, MD, has served as Founder and CEO of several venture-backed life science companies in San Diego. Dr. Dobak is the President of the JAKK Group, a life sciences technology accelerator, which has created several companies, including Lithera, INNERCOOL Therapies, and CryoGen/CryoCor. These companies have developed and marketed therapeutics, ranging from endovascular hypothermia to treat cardiac arrest to catheter-based treatments for cardiac arrhythmias. They have been financed by top tier investment firms and have achieved exits through acquisition and an IPO. Dr. Dobak and these companies are the recipients of several awards for entrepreneurship and innovation, including UCSD Connect’s Most Innovative New Product and MIT’s TR 100. Dr. Dobak received a bachelor’s degree from UCLA and a medical doctorate from UCSD.
Steven Kemper, CPA, MBA, M.S.
Chief Financial Officer
Steven Kemper’s career includes over thirty years in the financial management of rapidly growing companies in high technology environments ranging from the Fortune 100 to venture backed start-ups. He is President of Pacific Financial Consulting and Adjunct Professor of Finance at the University of San Diego. Mr. Kemper has raised over $650 million including three IPO’s in the medical devices and diagnostics industries. He was formerly Chief Financial Officer for GenMark Diagnostics (NASDAQ:GNMK) and DexCom, Inc. (NASDAQ:DXCM). Earlier in his career he led the financial team at General Instrument’s Satellite Television operations in San Diego, which was sold to Motorola and is now part of Google. Steven holds a bachelor’s degree from the University of California, San Diego, an MBA in Finance from Loyola Marymount University, a Master of Science in Accountancy from San Diego State University and is a licensed CPA.
Zuxu Yao, Ph.D.
Chief Scientific Officer
Dr. Yao has over 25 years of academic and industrial experience with a track record of successful development of various molecular diagnostic products. Prior to joining DermTech, Dr. Yao had served as Vice President of Assay Development at Nexogen, Associate Director of Research and Development at Adnavance Technologies, Principal Scientist (R&D) at Celula and Senior Staff Scientist (R&D) at Nanogen. Dr. Yao holds a PhD degree in Biochemistry from Memorial University of Newfoundland (Canada) and received post-doctoral research training at the School of Medicine, University of California, San Diego (UCSD) and at the National Institute of Basic Biology in Okazaki (Japan). He has published over 40 scientific papers in peer-reviewed journals and owns numerous patents on rapid nucleic acid extraction, nucleic acid target amplification and detection for diagnostic application.
Burkhard Jansen, M.D.
Chief Medical Officer
Burkhard Jansen, MD, is a melanoma expert with background as a tenured professor of both dermatology and clinical pharmacology with FDA experience. Dr. Jansen has served as founder, director, and senior executive of a number of dermatology and oncology focused life sciences companies, including Novelix, Avienne, and Oncogenex in the US, Canada, and Europe. Dr. Jansen received his medical doctorate and dermatology training from the Universities of Graz and Vienna in Austria, his postdoctoral science training at the University of Minnesota, and his executive business education at UCLA.
Chief Commercial Officer
Todd Wood brings more than 25 years of pharmaceutical and medical device commercialization experience to his position as Chief Commercial Officer at DermTech where he oversees the Sales and Marketing function. While leading commercial teams in Dermatology, Eye Care and Aesthetics, Todd has expanded and restructured large multibillion-dollar organizations such as Allergan’s Eye Care franchise and launched and/or aligned execution of multiple market leading products including Botox, Juvederm, Lumigan and Rhofade. Todd has built operational infrastructures in start-up organizations and developed business units in large transitioning companies. As an accomplished leader in the industry, he has developed a multitude of personnel to positions of greater responsibility. Todd has a track record of success in building highly effective organizations due to his ability to combine operational expertise and authentic leadership. Todd received a bachelor’s degree from Grand Valley State University.
Vice President, Lab Operations
Darryl Garrison has over 20 years of experience in the healthcare industry, including cancer diagnostics and CLIA laboratory operations. He was an original member of Clarient Diagnostic Services and later established NeoGenomics West Coast CLIA operations. He has served as founder, director and vice president for a number of CLIA laboratories, including Clarient, NeoGenomics, Pathway Genomics, Arista Molecular and VantagePoint Laboratories. He has a Bachelor of Science in Microbiology, a Master of Science in Molecular Biology and currently holds State CLS licenses in CA and NY.
Vice President, Marketing
Sarah Dion comes to DermTech with a successful track record of leading, innovation, development, and product commercialization in many fields of life science, including experience in pharmaceuticals, diagnostics and laboratory services. Her background includes work in research, product development, marketing, and leading a sales organization of over 85 personnel. Prior to DermTech, she held the position of Vice President Commercial Operations at LABS Inc. where she led the commercial team of sales, marketing, IT and client solutions. Mrs. Dion joined LABS after working as Senior Sales Director at Pathway Genomics where the sales team grew revenues and volume by over 2,000% year over year and was recognized by industry magazines as one of the fastest growing companies in the US. She holds a bachelor’s degree in Chemistry from Covenant College and an MBA from PLNU.
Vice President of Clinical Operations and Research Contracts
James Rock, currently serves as the Vice President of Clinical Operations and Research Contracts. He has over 15 years of experience having worked in clinical and business development capacities including partnering activities, raising capital and product development. He has been instrumental in bring several products to marking including OTC, prescription drugs, and novel in vitro diagnostics. Previously he was Vice President of Clinical Affairs for Trinity Biotech, Director of New Product Development and Interim CEO at Pacific Beach BioSciences, and Director of Clinical Development at MPEX Pharmaceuticals. Mr. Rock holds a Bachelor of Science from the University of Vermont, received his MSc degree from Springfield College, and his MBA from Pepperdine University.